Our History


1911 Establishment of the Company by Ioannis Lavidas

1914 Launch of Digitaline, a cardiovascular pharmaceutical product which opened a new era in modern therapeutics in Greece

1958 Launch of Nitroglycerin Controlled Release, opening a new chapter in the history of Cardiology

1976 Dr. Athanase Lavidas takes helm with new management team

1977 Collaboration with L’Oréal – first to sell cosmetics through pharmacies in Greece

1979 Completion of production unit for the manufacturing of pharmaceutical and cosmetic products. Launch of the antilice Ivaliten a blockbuster at the time

1985 Establishment of R&D department focused on drug delivery technologies

1988 Launch of Avon Cosmetics in Greece. Lavipharm creates a new distribution channel in the Greek market by introducing door-to-door sales

1989 Establishment of Laboratoires Lavipharm in Paris

1992 Joint Ventures with Synthélabo-France (Synthélabo -Lavipharm) and L’Oreal Cosmetique Active (Lavicosmetica). Launch of the dermocosmetic brand Castalia, developed by Lavipharm

1993 Completion of an integrated production unit for transdermals which remains until today one of the few in Europe

1994 Establishment of the wholesaling and distribution center (LAS)

1995 Listing of Lavipharm S.A. on the Athens Stock Exchange. Launch of nitroglycerin transdermal patch in Italy and France

1996 Acquisition of a U.S. based R&D unit specialised in TDDSs (now Lavipharm Laboratories Inc)

1997 Launch of patented acne epidermal patch developed in-house in 40 countries by L’Oreal

1999 Lavipharm was included in Europe’s 500 fastest growing companies

2000 Acquisition of Hitex (France) and 30% of Phasex (U.S.) entering the Super Critical Fluid Technologies (SCF) area

2002 Re-launch of the traditional Greek analgesic Algon®

2003 Nomination of a Business Award for Innovation

2004 Launch of Castalia’s products in the Chinese market

2006 FDA approval of Lavipharm’s fentanyl transdermal system in the USA. Lavipharm is listed as one of 1000 top companies that invest in the R&D Sector according to the European Innovation Scoreboard (EIS)

2007 Fentanyl transdermal system’s launch in Greece

2008 Fentanyl transdermal system’s launch in Germany. Co-marketing with Pfizer Hellas for Lavipharm’s Trinipatch™ Transdermal System in the Greek market

2009 Regulatory approval of fentanyl transdermal system in Austria, Belgium, Ireland, Italy, Norway, Portugal, Spain, Sweden and France

2010 DCP Regulatory approval for Lavipharm’s fentanyl transdermal system in 20 more countries  – Pfizer Hellas markets Lavipharm’s Dolfen™ in Greece

2011 Establishment of Lavipharm Srl in Forli, Italy

2012 Strategic Collaboration with the Belgian Company Tilman, Phytotherapy Specialists

2013 Pharma PLUS’ opens up to Pharmasists as new shareholders through Capital Increase